GSK is win­ning 70% of the RSV mar­ket, while Pfiz­er's launch has left it ‘dis­ap­point­ed’ so far

GSK has tak­en over a sig­nif­i­cant share of what’s ex­pect­ed to be a multi­bil­lion-dol­lar mar­ket for RSV pre­ven­ta­tives, turn­ing its vac­cine in­to a block­buster in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER